기본 통계
| LEI | 529900YOD61G7ECPV281 |
| CIK | 1607962 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to ReWalk Robotics Ltd.
SEC Filings (Chronological Order)
이 페이지는 다른 곳에서 제공하는 소유권 보고서를 제외한 SEC 보고서의 전체 리스트를 시간 순으로 정리한 것입니다.
| May 29, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Lifeward Ltd. (Exact name of the registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation) 001-36612 (Commission file number) 2 Cabot Rd., Hudson, MA (Address of principal executive offices) 01749 (Zip Code) Almog Adar, Chief Financial Officer, |
|
| May 29, 2026 |
Conflict Minerals Report of Lifeward Ltd. For the year ended December 31, 2025 Exhibit 1.01 Conflict Minerals Report of Lifeward Ltd. For the year ended December 31, 2025 Introduction This is the Conflict Minerals Report (the “CMR”) of Lifeward Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2025 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certain information |
|
| May 20, 2026 |
As filed with the Securities and Exchange Commission on May 20, 2026 As filed with the Securities and Exchange Commission on May 20, 2026 Registration No. |
|
| May 20, 2026 |
CALCULATION OF FILING FEE TABLES Lifeward Ltd. Table 1: Newly Registered Securities Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 Lifeward Ltd. Table 1: Newly Registered Securities Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value per ordinary share (1) Other 435,416 $ 6.26 $ 2,725,704.16 0.0001381 $ |
|
| May 20, 2026 |
AMENDMENT NO. 1 TO THE LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Exhibit 99.2 AMENDMENT NO. 1 TO THE LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN WHEREAS, Lifeward Ltd. (the “Company”) maintains the Lifeward Ltd. 2025 Incentive Compensation Plan (the “Plan”), which was previously adopted by the Board of Directors of the Company (the “Board”) and approved by the Company’s shareholders; WHEREAS, Section 15.1 of the Plan provides that the Board may amend the Pla |
|
| May 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact na |
|
| May 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 15, 2026 |
Exhibit 99.1 Lifeward Reports First Quarter 2026 Financial Results Oramed strategic transaction successfully closed and $10 million financing received Oratech acquisition brings $6.5 million in cash and promising Protein Oral Delivery™ biomed technology, with lead asset ORMD-0801 oral insulin set to commence Phase 2 study Acquired upper body exoskeleton technology addressing unmet need in 4.6 mill |
|
| May 15, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: March 31, 2026 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the transition perio |
|
| May 8, 2026 |
Lifeward Ltd. 2 Cabot Road Hudson, MA 01749 May 8, 2026 Lifeward Ltd. 2 Cabot Road Hudson, MA 01749 May 8, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Lifeward Ltd. Registration Statement on Form S-3 (File No. 333-295352) Filed on April 27, 2026 Ladies and Gentlemen: Reference is made to the Registration Statement on Form S-3 (File No. 333-295352) filed by Lif |
|
| April 27, 2026 |
As filed with the Securities and Exchange Commission on April 27, 2026 As filed with the Securities and Exchange Commission on April 27, 2026 Registration No. |
|
| April 27, 2026 |
Calculation of Filing Fee Tables S-3 Lifeward Ltd. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| April 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or other jurisdiction of incorporation or organization) (Com |
|
| March 31, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or other jurisdiction of incorporation or organization) (Com |
|
| March 25, 2026 |
FIRST AMENDMENT TO SHARE PURCHASE AGREEMENT Exhibit 2.1 FIRST AMENDMENT TO SHARE PURCHASE AGREEMENT THIS FIRST AMENDMENT TO SHARE PURCHASE AGREEMENT (this “Amendment”) dated and effective as of [●], 2026 (the “Effective Date”), amends that certain Share Purchase Agreement, dated January 12, 2026 (as amended to date, the “Purchase Agreement”), by and among Lifeward Ltd., a company limited by shares organized under the laws of the State of Is |
|
| March 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or other jurisdiction of incorporation or organization) (Com |
|
| March 25, 2026 |
ASSIGNMENT OF SHARE PURCHASE AGREEMENT Exhibit 2.2 ASSIGNMENT OF SHARE PURCHASE AGREEMENT This Assignment of Share Purchase Agreement (the “Assignment”) is made and entered into to be effective as of [ ], 2026 (“Effective Date”), by and between Oratech Pharma, Inc., a Nevada corporation (“Assignor”), and Oratech Ltd., a Company limited by shares organized under the laws of the State of Israel (the “Assignee”) and acknowledged by Lifewa |
|
| March 20, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or other jurisdiction of incorporation or organization) (Com |
|
| March 18, 2026 |
Exhibit 10.31 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SU |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name |
|
| March 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 18, 2026 |
Exhibit 99.1 Lifeward Reports Fourth Quarter and Full Year 2025 Financial Results Advancing transformation into a diversified biomedical innovation company with a clear path to cash flow positive Oramed strategic transaction receives shareholder approval; Lifeward gains new oral protein delivery technology platform Lifeward already executing new strategy through acquisition of powered upper-body e |
|
| March 18, 2026 |
SECURED PROMISSORY NOTE DUE THE EARLIER OF THE TRIGGER DATE AND AUGUST 12, 2026 Exhibit 10.32 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE BORROWER THAT S |
|
| March 18, 2026 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, no par value, of Lifeward Ltd. (the “Company,” “we” or “us”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This description is a summary and is qualified in its e |
|
| March 18, 2026 |
Exhibit 10.6 June 30, 2025 PERSONAL AND CONFIDENTIAL Larry Jasinski Re: Separation Agreement Dear Larry: As indicated in the earlier “notice of termination” provided to you pursuant to Section 9.4 of the Executive Employment Agreement between the Lifeward, Inc. f/k/a Argo Medical Technologies, Inc. (the “Company”) and you (the “Employment Agreement”), your employment with the Company will terminat |
|
| March 18, 2026 |
Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES EIGHTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Lifeward Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law. The |
|
| March 18, 2026 |
Exhibit 10.7 August 14, 2025 PERSONAL AND CONFIDENTIAL Larry Jasinski Re: Supplemental Release Dear Larry: As you are aware, your employment with Lifeward, Inc. f/k/a Argo Medical Technologies, Inc. (the “Company”) terminated, effective as of June 30, 2025 (such date, the “Separation Date”). On the Separation Date, you enter entered into a Separation Agreement dated June 30, 2025 (the “Separation |
|
| March 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2026 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| March 2, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 27, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2026 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 19, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 12, 2026 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2026 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| January 28, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 28, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 13, 2026 |
SENIOR SECURED CONVERTIBLE NOTE Exhibit 4.3 THE SECURITIES REFERENCED HEREIN HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH |
|
| January 13, 2026 |
ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Exhibit 4.4 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| January 13, 2026 |
Exhibit 99.1 Lifeward Enters Transformative Strategic Investment and Partnership Agreement with Oramed to Create a Diversified Biomedical Innovation Company Positions Lifeward as a MedTech platform with a clear path to cashflow positive and long- term Biotech upside potential Up to $47 million strategic investment from Oramed and another investor is intended to provide Lifeward cash runway to prof |
|
| January 13, 2026 |
Exhibit 10.1 FORM OF LOCK-UP AGREEMENT [ ], [ ] Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Attn: William Mark Grant; Almog Adar Email: [email protected]; [email protected] Ladies and Gentlemen: The undersigned signatory of this lock-up agreement (this “Lock-Up Agreement’’) understands that Lifeward Ltd., a company limited by shares organized under the laws of the St |
|
| January 13, 2026 |
ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Exhibit 4.2 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| January 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 12, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 13, 2026 |
Exhibit 2.1 Execution Version SHARE PURCHASE AGREEMENT among LIFEWARD LTD., ORATECH PHARMA, INC., and ORAMED PHARMACEUTICALS, INC. Dated as of January 12, 2026 Section 1. Definitions and Interpretative Provisions 1.1 Definitions 2 1.2 Other Definitional and Interpretative Provisions 14 Section 2. Description of Transaction 2.1 Purchase and Sale 15 2.2 Closing. 15 2.3 Payment of Purchase Price. 15 |
|
| January 13, 2026 |
PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Exhibit 4.1 EXHIBIT A NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTI |
|
| January 13, 2026 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 12, 2026, among Lifeward Ltd., a company organized under the laws of the State of Israel (the “Company”), each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”), and Oramed Pharmaceuti |
|
| January 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2026 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 2, 2026 |
As filed with the Securities and Exchange Commission on January 2, 2026 As filed with the Securities and Exchange Commission on January 2, 2026 Registration No. |
|
| January 2, 2026 |
Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 January 2, 2026 Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 January 2, 2026 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington, D.C. 20549-7553 Re: Lifeward Ltd. Registration Statement on Form S-3 Originally filed on May 15, 2025, as amended on January 2, 2026 (File No. 333-287314) Ladies and |
|
| January 2, 2026 |
Calculation of Filing Fee Tables S-3 Lifeward Ltd. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effec |
|
| December 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| December 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| November 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 14, 2025 |
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT Exhibit 10.1 FIRST AMENDMENT TO EMPLOYMENT AGREEMENT This First Amendment to Employment Agreement (this “Agreement”) is entered into and effective as of August 1, 2025 (the “Effective Date”), by and between Lifeward, Inc. (the “Company”), and Almog Adar (“Employee”). Employee and the Company shall be referred to herein, collectively as the “Parties” and individually as a “Party.” WHEREAS, the Part |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exac |
|
| November 14, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports Third Quarter 2025 Financial Results Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital s |
|
| November 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| October 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 16, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
Exhibit 99.4 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant - According to 102 Capital Gains Track (with Trustee) Participant: [•] Company: Lifeward Ltd. Notice: You have been granted the following Stock Option to purchase Ordinary Shares of the Company, par value NIS 1.75 per share, in accordance with the terms of the 2025 Incentive Compensation Plan and the Sub-Plan for Pa |
|
| August 25, 2025 |
LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Restricted Share Unit Grant Exhibit 99.5 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Restricted Share Unit Grant Participant: Company: Lifeward Ltd. Notice: You have been granted the following Restricted Share Units in accordance with the terms of the Plan, this Notice of Restricted Share Unit Grant and the Restricted Share Unit Award Agreement attached hereto as Attachment A (this Notice of Restricted Share Uni |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
Ex-Filing Fees CALCULATION OF FILING FEE TABLES S-8 LIFEWARD LTD. Table 1: Newly Registered and Carry Forward Securities Line Item Type Security Type Security Class Title Notes Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Newly Registered Securities Fees to be Paid Equity Ordinary Shares, par va |
|
| August 25, 2025 |
LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Exhibit 99.3 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Participant: [•] Company: Lifeward Ltd. Notice: You have been granted the following Non-Qualified Stock Option to purchase Shares in accordance with the terms of the Plan, this Notice of Option Grant and the Non-Qualified Stock Option Award Agreement attached hereto as Schedule A (this Notice of Option Grant, togeth |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Exhibit 99.2 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Option Grant Participant: [•] Company: Lifeward Ltd. Notice: You have been granted the following Incentive Stock Option to purchase Shares in accordance with the terms of the Plan, this Notice of Option Grant and the Incentive Stock Option Award Agreement attached hereto as Schedule A (this Notice of Option Grant, together with |
|
| August 25, 2025 |
As filed with the Securities and Exchange Commission on August 25, 2025 As filed with the Securities and Exchange Commission on August 25, 2025 Registration No. |
|
| August 25, 2025 |
Exhibit 99.6 LIFEWARD LTD. 2025 INCENTIVE COMPENSATION PLAN Notice of Restricted Share Unit Grant - According to 102 Capital Gains Track (with Trustee) Participant: Company: Lifeward Ltd. Notice: You have been granted the following Restricted Share Units (“RSUs”) in accordance with the terms of the 2025 Incentive Compensation Plan and the Sub-Plan for Participants in Israel (the “Sub-Plan” and, to |
|
| August 25, 2025 |
Exhibit 4.1 DESCRIPTION OF THE REGISTRANT'S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of the ordinary shares, par value NIS 1.75 per share, of Lifeward Ltd. (the “Company,” “we” or “us”) registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This description is a summary and is qu |
|
| August 14, 2025 |
Seventh Amended and Restated Articles of Association of the Company. Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES SEVENTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Lifeward Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law. The |
|
| August 14, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports Second Quarter 2025 Financial Results Achieves record number of ReWalk systems placed for Medicare beneficiaries since fee schedule established Third consecutive quarter of U.S. ReWalk pipeline growth with over 130 qualified leads in process Appoints new CEO and CFO to spearhead strategic change and accelerate growth MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, Au |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 14, 2025 |
Exhibit 10.3 LIFEWARD LTD. NOTICE OF NONQUALIFIED STOCK OPTION GRANT Participant: [•] Company: Lifeward Ltd. (the “Company”). Notice: You have been granted the following Nonqualified Stock Option to purchase Ordinary Shares, par value NIS 1.75 per share. This is an inducement grant, as described in NASDAQ Listing Rule 5635(c)(4), and shall be governed by this Notice of Nonqualified Stock Option Gr |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| August 13, 2025 |
Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership Exhibit 99.1 Lifeward Names Almog Adar as New CFO, Strengthening Executive Leadership MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, August 13, 2025 (GLOBE NEWSWIRE) - Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Almog Adar, who previously |
|
| August 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 1, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| June 26, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-288172 PROSPECTUS 4,000,000 Ordinary Shares 4,000,000 Warrants to Purchase Up to 4,000,000 Ordinary Shares 240,000 Placement Agent Warrants to Purchase Up to 240,000 Ordinary Shares 4,240,000 Ordinary Shares Issuable Upon Exercise of the Warrants and Placement Agent Warrants We are offering 4,000,000 ordinary shares, par value NIS 1.75 per shar |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| June 26, 2025 |
Form of Placement Agent Warrant. Exhibit 4.2 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: [] Issue Date: [], 2025 Initial Exercise Date: [], 2025 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| June 26, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June 25, 2025, between Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject |
|
| June 26, 2025 |
Exhibit 4.1 ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: [] Issue Date: [], 2025 Initial Exercise Date: [], 2025 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date se |
|
| June 26, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 25, 2025 |
Exhibit 10.30 Execution Version January 6, 2025 STRICTLY CONFIDENTIAL Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Attn: Larry Jasinski, Chief Executive Officer Dear Mr. Jasinski: This letter agreement (this “Agreement”) constitutes the agreement between Lifeward Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright shall serve as the exclusive underwrit |
|
| June 25, 2025 |
Exhibit 10.31 Execution Version May 13, 2025 STRICTLY CONFIDENTIAL Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Attn: Larry Jasinski, Chief Executive Officer Dear Mr. Jasinski: Reference is made to that certain engagement agreement (the “Engagement Agreement”), dated as of January 6, 2025, by and between Lifeward Ltd. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”). Def |
|
| June 25, 2025 |
Form of Pre-Funded Warrant (filed herewith). Exhibit 4.17 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 25, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Ca |
|
| June 25, 2025 |
Form of Placement Agent Warrant (filed herewith). Exhibit 4.19 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| June 25, 2025 |
Form of Securities Purchase Agreement (filed herewith). Exhibit 10.29 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June [●], 2025, between Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje |
|
| June 25, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 25, 2025. As filed with the U.S. Securities and Exchange Commission on June 25, 2025. Registration No. 333-288172 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lifeward Ltd. (Exact name of registrant as specified in its charter) State of Israel 3842 Not Applicable (State or Other Jurisdiction of Inc |
|
| June 25, 2025 |
Form of Warrant (filed herewith). Exhibit 4.18 ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Shareholde |
|
| June 23, 2025 |
June 23, 2025 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Washington, DC 20549 Re: Lifeward Ltd. Registration Statement on Form S-1 (File No. 333-288172) – Concurrence in Acceleration Request Ladies and Gentlemen: H.C. Wainwright & Co., LLC (“Wainwright”), solely acting as placement agent on a best efforts basis in an offering pursuant to the registration stat |
|
| June 23, 2025 |
[Remainder of Page Intentionally Blank] June 23, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D. |
|
| June 20, 2025 |
Form of Placement Agent Warrant (filed herewith). Exhibit 4.19 PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS PLACEMENT AGENT ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| June 20, 2025 |
Form of Warrant (filed herewith). Exhibit 4.18 ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Issue Date: [], 2025 [Initial Exercise Date: , 2025]1 THIS ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Shareholde |
|
| June 20, 2025 |
Employment Agreement, dated May 16, 2025, by and between Lifeward, Inc. and Mark Grant. Exhibit 10.29 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is dated as of May 16, 2025, by and between Lifeward, Inc., a Delaware corporation (the “Company”) (together with its present or future subsidiaries and affiliates, the “Group Companies”), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Mark Grant (the “Employee”) of Charlotte, North Carolina. WITNESS |
|
| June 20, 2025 |
Form of Securities Purchase Agreement (filed herewith). Exhibit 10.30 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of June [●], 2025, between Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subje |
|
| June 20, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 20, 2025. As filed with the U.S. Securities and Exchange Commission on June 20, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Lifeward Ltd. (Exact name of registrant as specified in its charter) State of Israel 3842 Not Applicable (State or Other Jurisdiction of Incorporation or (Primary St |
|
| June 20, 2025 |
Form of Pre-Funded Warrant (filed herewith). Exhibit 4.17 PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT LIFEWARD LTD. Warrant Shares: Initial Exercise Date: [], 2025 Issue Date: [], 2025 THIS PRE-FUNDED ORDINARY SHARE PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or |
|
| June 20, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price (1)(2) Fee Rate Amount of Registration Fee Ca |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| June 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| June 10, 2025 |
Goodwin Procter llp 3025 John F Kennedy Blvd Philadelphia, PA 19104 goodwinlaw.com +1 445 207 7800 June 10, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F. Street, N.E. Washington, D.C. 20549 Attention: Nicholas O’Leary Re: Lifeward Ltd. Draft Registration Statement on Form S-1 Submitted June 27, |
|
| June 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 2, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 28, 2025 |
Exhibit 1.01 Conflict Minerals Report of Lifeward Ltd. For the year ended December 31, 2024 Introduction This is the Conflict Minerals Report (the “CMR”) of Lifeward Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2024 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certain information |
|
| May 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Lifeward Ltd. (Exact name of the registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation) 001-36612 (Commission file number) 200 Donald Lynch Blvd. Marlborough, MA (Address of principal executive offices) 01752 (Zip Code) Mike Lawless, Chief Fi |
|
| May 27, 2025 |
DRS 1 filename1.htm Confidential Treatment Requested Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the U.S. Securities and Exchange Commission on May 27, 2025. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXC |
|
| May 21, 2025 |
May 21, 2025 Larry Jasinski Chief Executive Officer Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Re: Lifeward Ltd. Registration Statement on Form S-3 Filed May 15, 2025 File No. 333-287314 Dear Larry Jasinski: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remin |
|
| May 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 19, 2025 |
Exhibit 99.1 Lifeward Names Mark Grant as New CEO Industry veteran brings 30 years of commercial leadership experience MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, May 19, 2025 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has b |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact |
|
| May 15, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee C |
|
| May 15, 2025 |
Form of Indenture (filed herewith). Exhibit 4.19 Form of Indenture LIFEWARD LTD. and INDENTURE Dated as of , 20 TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 4 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 4 Section 2.01 Issuable in Series 4 Section 2.02 Establishment |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numbe |
|
| May 15, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports First Quarter 2025 Financial Results U.S. pipeline of ReWalk opportunities continues to build with over 120 qualified leads in process Closure of AlterG sites and resulting consolidation of resources and reduced expenditures yields improved operating expense trend Second consecutive quarter of AlterG revenue growth over 15% reflecting continued sales momentum MAR |
|
| April 15, 2025 |
Exhibit 99.1 Lifeward Launches Sales of the ReWalk 7 Personal Exoskeleton in U.S. Market Seventh generation of industry-leading personal exoskeleton is now available nationwide for individuals with spinal cord injury New and improved features streamline user experience for greater control, engagement, and confidence during walking in everyday environments MARLBOROUGH, Mass. and YOKNEAM ILLIT, Isra |
|
| April 15, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Num |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 7, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 7, 2025 |
Exhibit 19.1 LIFEWARD LTD. INSIDER TRADING POLICY This document sets forth the Insider Trading Policy (the “Policy”) of Lifeward Ltd. (“Lifeward”). The Policy establishes the policies and procedures that govern trading by Lifeward personnel in Lifeward securities and securities of any other company about which such personnel learns material, nonpublic information in the course of performing his or |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (Exact name |
|
| March 7, 2025 |
Exhibit 10.22 AMENDMENT #1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment #1 to the Executive Employment Agreement (this “Amendment”) is made and entered into on September 23, 2020, by and between ReWalk Robotics Inc. (formerly Argo Medical Technologies Inc.),a Delaware corporation (the “Company”), and Larry Jasinski (the “Employee”). The Company and the Employee shall each be referred to as a “ |
|
| March 7, 2025 |
Exhibit 10.1 AT THE MARKET OFFERING AGREEMENT March 7, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue, 3rd Floor New York, NY 10022 Ladies and Gentlemen: Lifeward Ltd., a corporation organized under the laws of the State of Israel (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used |
|
| March 7, 2025 |
Exhibit 99.1 Lifeward Ltd. Reports Fourth Quarter and Full Year 2024 Financial Results Record quarterly and annual revenue of $7.5M and $25.7M, respectively Continued strong growth in U.S. pipeline of ReWalk opportunities with over 110 qualified leads in process Strategic shift towards profitability: 2025 Sustainable Growth Plan focuses on growth of core product lines with a streamlined cost struc |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Israel 001-36612 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Numb |
|
| March 7, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No 333-263984 PROSPECTUS SUPPLEMENT (To Prospectus dated May 16, 2022) Up to $5,488,800 Ordinary Shares We have entered into an At The Market Offering Agreement (the “Sales Agreement”), dated March 7, 2025, with H. |
|
| March 7, 2025 |
Exhibit 10.23 CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. MANUFACTURING SERVICES AGREEMENT THIS MANUFACTURING SERVICES AGREEMENT (this “Agreement”) is made on October 3, 2024 (the “Effective Date”), by and between Lifeward, Inc., a Delaware corporation having |
|
| February 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 18, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 14, 2025 As filed with the Securities and Exchange Commission on February 14, 2025 Registration No. |
|
| February 14, 2025 |
[Remainder of Page Intentionally Blank] February 14, 2025 VIA EDGAR Division of Corporation Finance Office of Industrial Applications and Services Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| February 13, 2025 |
February 13, 2025 Michael Lawless Chief Financial Officer Lifeward Ltd. 200 Donald Lynch Blvd. Marlborough, MA 01752 Re: Lifeward Ltd. Registration Statement on Form S-1 Filed February 11, 2025 File No. 333-284843 Dear Michael Lawless: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for accelerati |
|
| February 11, 2025 |
As filed with the Securities and Exchange Commission on February 11, 2025 As filed with the Securities and Exchange Commission on February 11, 2025 Registration No. |
|
| February 11, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Lifeward Ltd. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee New |
|
| January 14, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| January 13, 2025 |
Lifeward Cancels Its Extraordinary General Meeting of Shareholders Exhibit 99.1 Lifeward Cancels Its Extraordinary General Meeting of Shareholders MARLBOROUGH, MA, and YOKNEAM ILIT, Israel, January 13, 2025 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), today announced that it has cancelled its previously announced Extraordinary General Meeting of Shareholders that had been scheduled for January 13, 2025. The Board of Directors of Lifeward (the “Bo |
|
| January 13, 2025 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| January 8, 2025 |
Form of Securities Purchase Agreement. Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of January 7, 2025, between Lifeward Ltd., a company organized under the laws of the State of Israel (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject t |
|
| January 8, 2025 |
Lifeward Ltd. 1,818,183 Ordinary Shares As filed pursuant to Rule 424(b)(5) Registration No. 333-263984 PROSPECTUS SUPPLEMENT (To Prospectus dated May 16, 2022) Lifeward Ltd. 1,818,183 Ordinary Shares We are offering 1,818,183 ordinary shares, par value NIS 1.75 per ordinary share, to certain institutional investors at an offering price of $2.75 per share. In a concurrent private placement, we are also selling to such purchasers warrant |
|
| January 8, 2025 |
Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Exhibit 99.1 Lifeward Announces $5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules MARLBOROUGH, MA, and YOKNEAM ILIT, Israel, January 7, 2025 – Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global market leader delivering life-changing solutions to revolutionize what is possible in rehabilitation, recovery, and the pursuit of life’s passions in the face o |
|
| January 8, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) |
|
| January 8, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| January 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2025 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File Nu |
|
| January 8, 2025 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| November 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| November 12, 2024 |
Exhibit 99.1 Lifeward Ltd. Reports Third Quarter 2024 Financial Results Second consecutive quarter of 20 ReWalk systems sold Robust growth in U.S. ReWalk pipeline of approximately 70 qualified leads for potential claim submission with Medicare and other U.S. payors MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, November 12, 2024 – Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global |
|
| November 12, 2024 |
Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES SIXTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF Lifeward Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law. The “ |
|
| November 12, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 Lifeward Ltd. (E |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2024 Lifeward Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission File N |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| August 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 15, 2024 |
Exhibit 99.1 Lifeward Reports Second Quarter 2024 Financial Results Record ReWalk revenue with 20 systems placed Q2’24 revenue of $6.7M up over 400% compared to $1.3M in Q2’23 Medicare claims for submissions from prior quarters beginning to be paid MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, August 15, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company”), a glo |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| August 14, 2024 |
Exhibit 10.1 EMPLOYMENT AND RELOCATION AGREEMENT This EMPLOYMENT AGREEMENT is dated as of July 17, 2024, by and between Lifeward, Inc., a Delaware corporation (the “Company”), with offices at 200 Donald Lynch Boulevard, Marlborough, MA 01752 and Almog Adar (the “Employee”) of Ein HaEmek, Israel. WITNESSETH: WHEREAS the Company desires to enter into employment with the Employee for the period provi |
|
| August 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 27, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 28, 2024 |
Exhibit 1.01 Conflict Minerals Report of ReWalk Robotics Ltd. For the year ended December 31, 2023 Introduction This is the Conflict Minerals Report (the “CMR”) of ReWalk Robotics Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2023 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certai |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ReWalk Robotics Ltd. (Exact name of the registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation) 001-36612 (Commission file number) 3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel (Address of principal executive offices) 2069203 (Zip Code) Mike |
|
| May 15, 2024 |
Exhibit 99.1 Lifeward Reports First Quarter 2024 Financial Results Q1’24 revenue of $5.3M is up 340% vs. Q1’23 and at the midpoint of Lifeward’s guidance range Newly established Medicare payment for ReWalk Personal Exoskeleton favorably impacts Q1’24 results Medicare Administrative Contractors (“MACs”) approve 14 claims since fee schedule established MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, May |
|
| May 15, 2024 |
Fifth Amended and Restated Articles of Association of the Company. Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ReWalk Robotics Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law |
|
| May 15, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (E |
|
| April 29, 2024 |
Fifth Amended and Restated Articles of Association of the Company.*** Exhibit 3.1 THE ISRAELI COMPANIES LAW A COMPANY LIMITED BY SHARES FIFTH AMENDED AND RESTATED ARTICLES OF ASSOCIATION OF ReWalk Robotics Ltd. GENERAL PROVISIONS 1. Definitions a) In these Articles the following terms shall bear the meaning ascribed to them below: “Alternate Director” is defined in Article 41. “Annual General Meeting” shall have the meaning assigned to such term in the Companies Law |
|
| April 19, 2024 |
Exhibit 99.1 Lifeward Announces the Appointment of Mike Swinford to its Board of Directors Experienced healthcare and rehabilitation technology professional brings more than 30 years of experience in commercialization and new business development MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, April 19, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™) (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global |
|
| April 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| April 3, 2024 |
Exhibit 99.1 Investor Presentation April 2024 we are partners in energy storage Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements contained in this presentation oth |
|
| April 3, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 27, 2024 |
Exhibit 21.1 List of Subsidiaries of ReWalk Robotics Ltd. Name of Subsidiary Place of Incorporation Lifeward, Inc. Delaware, United States Lifeward CA, Inc. Delaware, United States Lifeward GmbH Germany |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 27, 2024 |
Exhibit 99.1 Lifeward Reports Fourth Quarter and Full Year 2023 Financial Results Highest quarterly and annual revenue in the history of Lifeward Commercial and operational integration complete; synergies expected to yield $3 million in annual net savings MARLBOROUGH, MA, and YOKNEAM ILLIT, Israel, February 27, 2024 – ReWalk Robotics Ltd. (DBA Lifeward™), (Nasdaq: LFWD) (“Lifeward” or the “Company |
|
| February 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exa |
|
| January 30, 2024 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 29, 2024 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| January 30, 2024 |
ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward Exhibit 99.1 ReWalk Robotics Transforms Company Identity, Rebrands as Lifeward Lifeward brand reflects the Company’s commitment to pioneering innovative technology to empower the pursuit of life’s ambitions in the face of physical limitation or disability. The complete rebrand includes new name, stock ticker, logo, website launch, and corporate messaging. MARLBOROUGH, MA, BERLIN, Germany, and YOKN |
|
| December 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 14, 2023 |
Exhibit 99.1 ReWalk Robotics Reports Third Quarter 2023 Financial Results Record Quarterly Revenue of $4.4 Million Successful Completion of AlterG Acquisition and Significant Progress of Integration Major Advancement in Efforts to Attain Medicare Payment Coverage of Exoskeletons MARLBOROUGH, Mass., BERLIN, Germany and YOKNEAM ILLIT, Israel, November 14, 2023 - ReWalk Robotics Ltd. (Nasdaq: RWLK) ( |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics |
|
| November 14, 2023 |
Exhibit 10.2 REWALK ROBOTICS LTD. 2014 INCENTIVE COMPENSATION PLAN Notice of Restricted Stock Unit Grant (Inducement Award) Participant: Company: [•] ReWalk Robotics Ltd. Notice: You have been granted the following Restricted Stock Units. This is an inducement grant, as described in NASDAQ Listing Rule 5635(c)(4). Accordingly, the Restricted Stock Units have been granted outside of the Plan. Howev |
|
| November 14, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT (the “Agreement”) is dated as of August 11, 2023, by and between ReWalk Robotics, Inc., a Delaware corporation (the “Company”), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Charles Remsberg (the “Employee”) of 770 Luce Court, Mountain View, CA 94041. WITNESSETH: WHEREAS the Company desires to enter into employment wi |
|
| October 27, 2023 |
ALTERG INC. FOR THE QUARTER ENDED JUNE 30,2023 TABLE OF CONTENTS Exhibit 99.2 ALTERG INC. FOR THE QUARTER ENDED JUNE 30,2023 TABLE OF CONTENTS Page No. PART I FINANCIAL INFORMATION 2 ITEM 1. FINANCIAL STATEMENTS (unaudited) 2 CONDENSED BALANCE SHEETS - JUNE 30, 2023 AND DECEMBER 31, 2022 2 CONDENSED STATEMENTS OF OPERATIONS - SIX MONTHS ENDED JUNE 30, 2023 AND 2022 4 CONDENSED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED SHARES, COMMON SHARES AND SHAREHOLDERS |
|
| October 27, 2023 |
ReWalk Robotics Ltd. Unaudited Pro Forma Condensed Combined Financial Information Exhibit 99.3 ReWalk Robotics Ltd. Unaudited Pro Forma Condensed Combined Financial Information Introduction On August 8, 2023, ReWalk Robotics Ltd. (the “Parent”, “Company”, "ReWalk") entered into an Agreement and Plan of Merger (the “Merger Agreement”) with AlterG Inc., a Delaware corporation ("AlterG”), and Atlas Merger Sub, Inc. (“Merger Sub”), a Delaware corporation and wholly owned subsidiary |
|
| October 27, 2023 |
Exhibit 99.1 ALTERG INC. FINANCIAL STATEMENTS FOR THE YEARS ENDED DECEMBER 31, 2022 AND 2021 U.S. DOLLARS IN THOUSANDS ALTERG INC. INDEX Page Report of Independent Auditors 3 Balance Sheets 4 Statements of Operations 5 Statements of changes in Redeemable Convertible Preferred Shares, Common Shares and Shareholders' Deficit 6 Statements of Cash Flows 7 Notes to Financial Statements 8 - 29 - - - - - |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorpo |
|
| October 13, 2023 |
ReWalk Robotics Investor Presentation October 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK Exhibit 99.1 ReWalk Robotics Investor Presentation October 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements co |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| October 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 6, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 28, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan, Wolff & Cohen, P.C. 500 Fifth Avenue New York, NY 10110 (212) 986-6000 (Name, Address |
|
| September 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Def |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 4, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| August 11, 2023 |
Exhibit 10.1 AMENDMENT #1 TO EMPLOYMENT AGREEMENT This Amendment #1 to the Employment Agreement (this “Amendment”) is made and entered into on May 4, 2023, by and between ReWalk Robotics Ltd., a company organized under the laws of the State of Israel (the “Company”), and Almog Adar (the “Employee”). The Company and the Employee shall each be referred to as a “Party” and shall together be referred |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 11, 2023 |
Exhibit 99.1 ReWalk Robotics Reports Second Quarter 2023 Financial Results Revenue in Line with Prior Financial Guidance Continued Progress with CMS in Establishment of Medicare Benefit Category for Exoskeletons Pending Acquisition of AlterG Expected to Contribute to ReWalk Financial Results Starting in Q3’23 MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILLIT, Israel, August 11, 2023 - ReWalk Ro |
|
| August 11, 2023 |
Exhibit 99.1 ReWalk Robotics Announces Closing of Acquisition of AlterG Combined Company Expected to Expand Access for Patients to Innovative Rehabilitation Technologies for Use in Clinics and the Home Charles Remsberg Appointed Chief Sales Officer at ReWalk Robotics MARLBOROUGH, MA, BERLIN, Germany, and YOKNEAM ILLIT, Israel (August 11, 2023) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or “th |
|
| August 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exa |
|
| August 9, 2023 |
Exhibit 99.2 Confidential – ReWalk Robotics 2023 ReWalk Robotics Acquisition of AlterG Conference Call and Webcast August 9, 2023 Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| August 9, 2023 |
Exhibit 2.1 Execution Version Agreement and Plan of Merger by and among ReWalk Robotics, Inc., Atlas Merger Sub, Inc., AlterG, Inc. and Shareholder Representative Services LLC, as the Securityholder Representative August 8, 2023 THIS IS A DRAFT AGREEMENT ONLY AND DELIVERY OR DISCUSSION OF THIS DRAFT AGREEMENT SHALL NOT BE CONSTRUED AS AN OFFER OR COMMITMENT WITH RESPECT TO THE PROPOSED TRANSACTION |
|
| August 9, 2023 |
Exhibit 99.1 ReWalk Robotics to Acquire AlterG; Acquisition Builds Commercial Scale and Accelerates Path to Profitability Combined Company Expands Patient and Clinician Access to Innovative Rehabilitation Technologies for Home and Clinic Use Transaction Projected to Increase Revenue Growth and Improve Operating Margin, While Reducing Cash Burn Rate MARLBOROUGH, MA, BERLIN, Germany, and YOKNEAM ILL |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| August 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION August 2, 2023 ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934 ReWalk Robotics Ltd. |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| July 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) State of Israel (State or other jurisdiction of incorporation or organization) 001-36612 (Commission file number) Not applicable (IRS Employer Identification No.) 3 Hatnufa Street, Floor 6, Yokneam Ilit, Israel (Ad |
|
| May 30, 2023 |
Exhibit 1.01 Conflict Minerals Report of ReWalk Robotics Ltd. For the year ended December 31, 2022 Introduction This is the Conflict Minerals Report (the “CMR”) of ReWalk Robotics Ltd. (the “Company,” “we” or “us” or “our”) for calendar year 2022 in accordance with Rule 13p-1 (the “Rule”) under the Securities Exchange Act of 1934, as amended (the “1934 Act”). The Rule requires disclosure of certai |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| May 11, 2023 |
Exhibit 99.1 ReWalk Robotics Reports First Quarter 2023 Financial Results On-Track Start to Fiscal Year with Progress in Advancing Reimbursement Coverage for Medicare Beneficiaries MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILLIT, Israel, May 11, 2023 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a leading provider of innovative technologies that enable mobility and wellne |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (E |
|
| May 1, 2023 |
Exhibit 10.25 AMENDMENT #1 TO EXECUTIVE EMPLOYMENT AGREEMENT This Amendment #1 to the Executive Employment Agreement (this “Amendment”) is made and entered into on September 23, 2020, by and between ReWalk Robotics Inc. (formerly Argo Medical Technologies Inc.), a Delaware corporation (the “Company”), and Larry Jasinski (the “Employee”). The Company and the Employee shall each be referred to as a |
|
| April 28, 2023 |
Exhibit 99.1 ReWalk Robotics Investor Presentation April 2023 Confidential – ReWalk Robotics 2023 NASDAQ:RWLK Forward Looking Statements This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities Exchange Act of 1934. All statements cont |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 14, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission F |
|
| March 9, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan, Wolff & Cohen, P.C. 500 Fifth Avenue New York, NY 10110 (212) 986-6000 (Name, Address |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 23, 2023 |
Exhibit 99.1 ReWalk Robotics Reports Fourth Quarter and Full Year 2022 Financial Results Strong Conclusion to 2022 – Q4’22 Revenue Highest Since Start of COVID-19 Pandemic Record Quarterly MyoCycle Sales Supplement Improved Exoskeleton Revenue MARLBOROUGH, Mass. BERLIN, Germany and YOKNEAM ILIT, Israel, February 23, 2023 - ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Company”), a medical |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT OR SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics Ltd. (Exa |
|
| February 22, 2023 |
Exhibit 99.2 February 22, 2023 Jeffrey Dykan Independent Chairman of the Board ReWalk Robotics Limited 3 Hatnufa Street, Floor 6 Yokneam Ilit, Israel 2069203 To the Board of Directors of ReWalk Robotics Limited (the “Company”): As you are aware, The Lind Partners, LLC and its affiliates (“Lind”) is the largest shareholder and a passionate supporter of ReWalk, holding 9,362,017 shares for 15.1% in |
|
| February 22, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP Activist Investment . UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) Christopher P. Davis Kleinberg, Kaplan, Wolff & Cohen, P.C. 500 Fifth Avenue New York, NY 10110 (212) 986-6000 (Name, Addres |
|
| February 13, 2023 |
RWLK / Rewalk Robotics Ltd / Lind Global Fund II LP - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ReWalk Robotics Ltd. (Name of Issuer) Ordinary shares, par value NIS 0.25 (Title of Class of Securities) M8216Q200 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the ap |
|
| February 13, 2023 |
EX-99.1 2 exhibit99-1.htm JOINT FILING AGREEMENT BY AND AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Ordinary shares, par value NIS 0.25, of ReWalk Robotics Ltd. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedul |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| December 22, 2022 |
Exhibit 99.1 ReWalk Announces Extension of Share Repurchase Program Reflects Confidence in Long-Term Potential of ReWalk MARLBOROUGH, Mass., BERLIN, Germany, and YOKNEAM ILIT, Israel, December 22, 2022 (GLOBE NEWSWIRE) - ReWalk Robotics Ltd. (Nasdaq: RWLK) (the ?Company? or ?ReWalk?), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced |
|
| November 7, 2022 |
Exhibit 99.1 ReWalk Robotics Reports Third Quarter 2022 Financial Results ReWalk Has Submitted the First Case to Medicare Administrative Contractors (MACs) for Coverage and Reimbursement of the ReWalk Exoskeleton for Medicare Beneficiaries As of November 4th, ReWalk Has Repurchased $0.9 Million of Common Stock Since Initiation of Its Program German Federal Social Court Hearing on November 10th wit |
|
| November 7, 2022 |
Exhibit 10.2 Employee RSU REWALK ROBOTICS LTD. 2014 INCENTIVE COMPENSATION PLAN Notice of Restricted Stock Unit Grant (Inducement Award) Participant: [?] Company: ReWalk Robotics Ltd. Notice: You have been granted the following Restricted Stock Units. This is an inducement grant, as described in NASDAQ Listing Rule 5635(c)(4). Accordingly, the Restricted Stock Units have been granted outside of th |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36612 ReWalk Robotics |
|
| November 7, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This EMPLOYMENT AGREEMENT is dated as of September 19, 2022, by and between ReWalk Robotics, Inc., a Delaware corporation (the "Company"), with offices at 200 Donald Lynch Boulevard, Marlboro, MA 01752 and Michael A. Lawless (the "Employee") of Medfield, MA. WITNESSETH: WHEREAS the Company desires to enter into employment with the Employee for the period provided |
|
| October 14, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commission |
|
| September 28, 2022 |
REWALK TAKES ANOTHER STEP TOWARD MEDICARE COVERAGE Exhibit 99.1 REWALK TAKES ANOTHER STEP TOWARD MEDICARE COVERAGE ? ReWalk to submit first cases for Medicare coverage through Medicare Administrative Contractors (MACs) ? Centers for Medicare and Medicaid Services (CMS) affirms that the MACs have discretion to cover and reimburse the ReWalk exoskeleton ? CMS also plans to further deliberate on a benefit category designation for the ReWalk exoskelet |
|
| September 28, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 2, 2022 ReWalk Robotics Ltd. (Exact name of registrant as specified in its charter) Israel 001-36612 Not applicable (State or Other Jurisdiction of Incorporation) (Commissio |
|
| September 6, 2022 |
As filed with the Securities and Exchange Commission on September 6, 2022 As filed with the Securities and Exchange Commission on September 6, 2022 Registration No. |
